Mantra Bio Inc., of San Francisco, plans to take its new $25 million series A financing and advance its pipeline and partnering efforts for engineering targeted exosome vehicles. The company platform integrates computational approaches, wet biology and robotics to leverage exosome diversity and enable rational design of therapeutics for a range of tissue and cellular targets.
Nura Bio Inc., a company working to discover and develop new neuroprotective medicines, has closed a $73 million series A financing that President and CEO Alpna Seth said would help her team advance a multitarget pipeline, initially led by an inhibitor of the sterile alpha TIR motif protein 1 inhibitor (SARM1).
DUBLIN – Versant Ventures is committing $35 million in series A funding to Bright Peak Therapeutics Inc., which is developing a pipeline of engineered cytokines that are produced using a novel chemical synthesis technique rather than the recombinant methods that have underpinned more than four decades of biotechnology development.
LONDON – Enthera Pharmaceuticals Srl has announced the largest international series A to date for an Italian biotech, closing a €28 million (US$32.9 million) round, to take programs in type 1 diabetes and inflammatory bowel disease (IBD) into phase I development.
LONDON - The combined force of Belgian life sciences has been brought together in the launch of Exevir Bio BV, which arrives on the scene with a €23 million (US$27 million) series A and ready for a phase I study of its novel antiviral therapy in hospitalized COVID-19 patients.
As Carmel, Ind.-based MBX Biosciences Inc., taking aim at rare endocrine diseases, disclosed $34.6 million in a series A financing, CEO and co-founder Kent Hawryluk told BioWorld that “everyone on the leadership team we’ve worked with in prior lives, so to speak,” adding that he’s “excited to have the band back together.”